Transpire Bio, a clinical-stage biopharmaceutical company, shared that its abbreviated new drug application for fluticasone furoate, umeclidinium and vilanterol inhalation powder has been accepted for ...
Transpire Bio's ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
SUNRISE, Fla., May 11, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today ...
Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that the U.S. FDA has completed a ...
(MENAFN- GlobeNewsWire - Nasdaq) SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for ...
SUNRISE, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., a U.S. based, clinical-stage, revenue-generating biopharmaceutical company focused on developing inhaled therapeutics for ...
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic ...
SUNRISE, Fla., April 28, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, has opened ...
Transpire Bio has licensed an inhaled PDE4 inhibitor from China’s Intragrand Pharma as a potential treatment for idiopathic pulmonary fibrosis (IPF), investigating a target already being pursued by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results